Veracyte, Inc. raised revenue guidance for the year 2022. The company is raising full-year 2022 total revenue expectations to $288 million to $293 million, representing year-over-year growth of 31% to 33%, assuming currency rates as of November 2, 2022. This represents an improved outlook compared to prior guidance of $272 million to $280 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.35 USD | +0.79% | +5.39% | -26.03% |
04-15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
02-26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.03% | 1.56B | |
-16.10% | 11.41B | |
+67.65% | 3.81B | |
-14.31% | 2.16B | |
+36.95% | 1.19B | |
-2.40% | 760M | |
-19.00% | 506M | |
-38.57% | 444M | |
+13.72% | 339M | |
+15.53% | 227M |
- Stock Market
- Equities
- VCYT Stock
- News Veracyte, Inc.
- Veracyte, Inc. Raises Revenue Guidance for the Year 2022